Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Published:2021-11 Issue:11 Volume:22 Page:1530-1540
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Fennell Dean A,Ewings Sean,Ottensmeier Christian,Califano Raffaele,Hanna Gerard G,Hill Kayleigh,Danson Sarah,Steele Nicola,Nye Mavis,Johnson Lucy,Lord Joanne,Middleton Calley,Szlosarek Peter,Chan Sam,Gaba Aarti,Darlison Liz,Wells-Jordan Peter,Richards Cathy,Poile Charlotte,Lester Jason F,Griffiths Gareth,Price Gillian,Shaw Paul,Cave Judith,Naik Jay,Ford Amy,Geldhart Tom,Dancey Gairin,Papadatos Dionysis,Polychronis Andy,Jankowska Petra,Scott Angela,Gardiner Jill,Cominos Mathilda,Campbell Lynn,MacGregor Carol,Mullholand Lois,Chitnis Meenali,Dougherty Gary

Funder

Cancer Research UK

Publisher

Elsevier BV

Subject

Oncology

Reference19 articles.

1. Novel insights into mesothelioma biology and implications for therapy;Yap;Nat Rev Cancer,2017

2. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol,2003

3. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial;Krug;Lancet Oncol,2015

4. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial;Maio;Lancet Oncol,2017

5. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis;Mansfield;J Thorac Oncol,2014

Cited by 150 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival prediction in peritoneal mesothelioma: a nomogram based on SEER data and a Chinese cohort;Frontiers in Endocrinology;2024-09-06

2. Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study;Japanese Journal of Clinical Oncology;2024-09-03

3. Further insights into MARS 2;The Lancet Respiratory Medicine;2024-09

4. Case report: complete response and long-term survival on third-line immunotherapy in patient with pleural mesothelioma;Frontiers in Oncology;2024-08-29

5. A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma;Nature Communications;2024-08-21